---
figid: PMC9560885__10555_2022_10066_Fig2_HTML
pmcid: PMC9560885
image_filename: 10555_2022_10066_Fig2_HTML.jpg
figure_link: /pmc/articles/PMC9560885/figure/Fig2/
number: Fig. 2
figure_title: ''
caption: 'Estrogen receptor signaling pathways: genomic or NISS pathways and the non-genomic
  or MISS pathway. AKT, protein kinase B; CoA, co-activator; CoR, co-activator receptor;
  CDK4/6, cyclin-dependent kinase 4/6; ER, estrogen receptor; ERE, estrogen responsive
  element; FGFR, fibroblast growth factor receptor; HER2, epidermal growth factor
  receptor 2; IGF1, insulin growth factor 1; MISS, membrane-initiated steroid signaling;
  mTORi, mammalian target of rapamycin inhibitors; MAPK, mitogen-activated protein
  kinase; NISS, nuclear-initiated steroid signaling; PI3Ki, phosphoinositide 3-kinase
  inhibitor; TFs, transcription factors'
article_title: 'The race to develop oral SERDs and other novel estrogen receptor inhibitors:
  recent clinical trial results and impact on treatment options.'
citation: Yating Wang, et al. Cancer Metastasis Rev. 2022 Oct 14 ;41(4):975-990.
year: '2022'

doi: 10.1007/s10555-022-10066-y
journal_title: Cancer Metastasis Reviews
journal_nlm_ta: Cancer Metastasis Rev
publisher_name: Springer US

keywords:
- Selective estrogen receptor degraders
- Clinical trials
- Protein degradation
- Oral SERDs
- PROTC
- LYTAC
- RIBOTAC
- Aptamers

---
